$50.61
2.795.83%
At Close: -
$50.61
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Ionis Pharmaceuticals
IONSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Ionis Pharmaceuticals (NASDAQ:IONS) Stock, Analyst Ratings, Price Targets, Forecasts
Ionis Pharmaceuticals Inc has a consensus price target of $57.32 based on the ratings of 25 analysts. The high is $88 issued by Wells Fargo on May 4, 2023. The low is $27 issued by SVB Leerink on February 23, 2023. The 3 most-recent analyst ratings were released by Needham, B of A Securities, and Jefferies on July 22, 2024, July 16, 2024, and July 16, 2024, respectively. With an average price target of $67.33 between Needham, B of A Securities, and Jefferies, there's an implied 33.04% upside for Ionis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
B of A Securities
Jefferies
Stifel
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Ionis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | 18.55% | Needham | Joseph Stringer | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 32.38% | B of A Securities | Jason Gerberry | $64 → $67 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 48.19% | Jefferies | Akash Tewari | $29 → $75 | Upgrade | Underperform → Buy | Get Alert |
| 06/27/2024 | Buy Now | 4.72% | Stifel | Paul Matteis | $50 → $53 | Maintains | Hold | Get Alert |
| 06/14/2024 | Buy Now | — | Bernstein | William Pickering | — | Upgrade | Underperform → Market Perform | Get Alert |
| 06/03/2024 | Buy Now | 18.55% | Needham | Joseph Stringer | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 62.02% | Wells Fargo | Yanan Zhu | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 48.19% | Oppenheimer | Jay Olson | $72 → $75 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 42.26% | Oppenheimer | Jay Olson | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | Buy Now | 28.43% | Oppenheimer | Jay Olson | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 24.48% | Piper Sandler | Do Kim | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/01/2024 | Buy Now | 8.67% | JP Morgan | Jessica Fye | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 38.31% | RBC Capital | Luca Issi | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 22.51% | Piper Sandler | Do Kim | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | 22.51% | B of A Securities | Jason Gerberry | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | -1.21% | Stifel | Paul Matteis | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -44.67% | Goldman Sachs | Salveen Richter | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | Buy Now | -5.16% | Morgan Stanley | Michael Ulz | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 2.75% | B of A Securities | Jason Gerberry | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | Buy Now | 28.43% | RBC Capital | Luca Issi | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | 24.48% | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
| 09/27/2023 | Buy Now | -11.08% | Morgan Stanley | Michael Ulz | $42 → $45 | Maintains | Equal-Weight | Get Alert |
| 09/27/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 18.55% | Citigroup | David Lebowitz | $36 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | Buy Now | 14.6% | Piper Sandler | Do Kim | → $58 | Assumes | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 28.43% | RBC Capital | Luca Issi | → $65 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | -28.87% | Citigroup | David Lebowitz | $30 → $36 | Upgrade | Sell → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 73.88% | Wells Fargo | Vanck Zhu | $92 → $88 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | -26.89% | Barclays | Gena Wang | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | -17.01% | Morgan Stanley | Michael Ulz | $40 → $42 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | -38.75% | Bernstein | William Pickering | → $31 | Initiates | → Underperform | Get Alert |
| 02/23/2023 | Buy Now | -46.65% | SVB Leerink | Mani Foroohar | $34 → $27 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 28.43% | RBC Capital | Luca Issi | → $65 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | 32.38% | BMO Capital | Gary Nachman | $70 → $67 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -20.96% | Barclays | Gena Wang | $44 → $40 | Maintains | Equal-Weight | Get Alert |
| 02/23/2023 | Buy Now | 18.55% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | -32.82% | SVB Leerink | Joseph Schwartz | $33 → $34 | Maintains | Market Perform | Get Alert |
| 01/23/2023 | Buy Now | -34.8% | SVB Leerink | Mani Foroohar | $32 → $33 | Maintains | Market Perform | Get Alert |
| 01/19/2023 | Buy Now | 22.51% | Piper Sandler | Do Kim | $60 → $62 | Maintains | Overweight | Get Alert |
| 12/21/2022 | Buy Now | -20.96% | Morgan Stanley | Michael Ulz | $56 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/10/2022 | Buy Now | 10.65% | Morgan Stanley | Andrew Galler | $57 → $56 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | -38.75% | Citigroup | David Lebowitz | $28 → $31 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | -48.63% | SVB Leerink | Mani Foroohar | $30 → $26 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 12.63% | Morgan Stanley | Andrew Galler | $30 → $57 | Upgrade | Underweight → Overweight | Get Alert |
| 08/10/2022 | Buy Now | -44.67% | Citigroup | David Lebowitz | $26 → $28 | Maintains | Sell | Get Alert |
| 08/10/2022 | Buy Now | 26.46% | RBC Capital | Luca Issi | $67 → $64 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 14.6% | Piper Sandler | Do Kim | $55 → $58 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 16.58% | Oppenheimer | Justin Kim | → $59 | Assumes | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | -46.65% | SVB Leerink | Mani Foroohar | $26 → $27 | Maintains | Market Perform | Get Alert |
| 05/09/2022 | Buy Now | -40.72% | Morgan Stanley | David Lebowitz | $31 → $30 | Maintains | Underweight | Get Alert |
| 04/01/2022 | Buy Now | -48.63% | SVB Leerink | Mani Foroohar | $29 → $26 | Maintains | Market Perform | Get Alert |
| 03/01/2022 | Buy Now | 26.46% | Guggenheim | Debjit Chattopadhyay | → $64 | Initiates | → Buy | Get Alert |
| 03/01/2022 | Buy Now | -48.63% | Citigroup | David Lebowitz | → $26 | Initiates | → Sell | Get Alert |
| 02/25/2022 | Buy Now | -42.7% | SVB Leerink | Mani Foroohar | $34 → $29 | Maintains | Market Perform | Get Alert |
| 02/01/2022 | Buy Now | -40.72% | B of A Securities | Jason Gerberry | $40 → $30 | Downgrade | Buy → Underperform | Get Alert |
| 12/17/2021 | Buy Now | -32.82% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
| 12/14/2021 | Buy Now | — | William Blair | Myles Minter | — | Upgrade | Market Perform → Outperform | Get Alert |
| 12/08/2021 | Buy Now | -28.87% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
| 11/04/2021 | Buy Now | 18.55% | Needham | Joseph Stringer | — | Maintains | Buy | Get Alert |
| 11/04/2021 | Buy Now | -22.94% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
| 10/12/2021 | Buy Now | -38.75% | Morgan Stanley | David Lebowitz | — | Maintains | Underweight | Get Alert |
| 08/19/2021 | Buy Now | 34.36% | BMO Capital | Gary Nachman | — | Maintains | Outperform | Get Alert |
| 08/05/2021 | Buy Now | -24.92% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS) stock?
The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by Needham on July 22, 2024. The analyst firm set a price target for $60.00 expecting IONS to rise to within 12 months (a possible 18.55% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by Needham, and Ionis Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on July 16, 2024 when Jefferies raised their price target to $75. Jefferies previously had an underperform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on December 21, 2022 when Morgan Stanley changed their price target from $56 to $40 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a reiterated with a price target of $60.00 to $60.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $50.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.